RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNA...
WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.
"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."
About RXI-109
RXi Pharmaceuticals' first clinical program involves RXI?109, a self-delivering RNAi compound (sd?rxRNA®) developed for the reduction of dermal scarring. RXI?109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI?109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein and on the mRNA that controls production of this protein.
RXi's sd?rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies. This allows sd?rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI?109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop RXI-109 and our other product candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties; the possibility that other companies or organizations may assert patent rights preventing us from developing our products; risks related to our ability to successfully list our securities on a national securities exchange and statements about other future expectations. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation
Copyright 2014 PR Newswire
WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.
"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."
About RXI-109
RXi Pharmaceuticals' first clinical program involves RXI?109, a self-delivering RNAi compound (sd?rxRNA®) developed for the reduction of dermal scarring. RXI?109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI?109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein and on the mRNA that controls production of this protein.
RXi's sd?rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies. This allows sd?rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI?109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop RXI-109 and our other product candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties; the possibility that other companies or organizations may assert patent rights preventing us from developing our products; risks related to our ability to successfully list our securities on a national securities exchange and statements about other future expectations. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation
Copyright 2014 PR Newswire
